Use of radiation with or without WR-2721 in advanced rectal cancer

Authors

  • T. Liu MD,

    1. Department of Radiation Oncology, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
    Search for more papers by this author
  • Y. Liu MD,

    1. Department of Radiation Oncology, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
    Search for more papers by this author
  • S. He MD,

    1. Department of Radiation Oncology, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
    Search for more papers by this author
  • Z. Zhang MD,

    1. Department of Radiation Oncology, Cancer Hospital, Shanghai Medical University, Shanghai, People's Republic of China
    Search for more papers by this author
  • M. M. Kligerman MD

    Corresponding author
    1. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
    • Hospital of the University of Pennsylvania, Department of Radiation Oncology, 3400 Spruce Street, Philadelphia, PA 19104-4283
    Search for more papers by this author

Abstract

One hundred patients with inoperable, unresectable, or recurrent adenocarcinoma of the rectum were stratified and randomized to WR-2721 plus radiation therapy (WR + RT) or radiation therapy (RT) only treatment arms. The protector, WR-2721, was administered at a dose of 340 mg/m2 15 minutes before RT, 4 days a week for 5 weeks. The entire pelvis received 225 cGy per fraction for a total of 4500 cGy. The RT only group received the same treatment schedule. After this, both groups received a conedown of 720 cGy in 4 fractions. Inoperable and unresectable cases received a second conedown of 720 cGy. No moderate or severe pelvic normal tissue late effects were seen in the 34 evaluable patients in the combination group. However, in the RT only group, 5 of 37 evaluable patients exhibited late effects of moderate or severe degree. This difference was statistically significant (P = 0.03). There was no evidence of tumor protection by WR-2721. Sixteen percent of patients randomized to the WR + RT group had a complete response compared with 10% in the RT only group. The conditions of 12 patients of 100 became operable and 8 were resected. Seven of these patients remain free of recurrence.

Ancillary